{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:45:36Z","timestamp":1792593936962,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>In AL amyloidosis, advanced renal disease can impact treatment options and cause significant morbidity. Patients with ESRD requiring dialysis are a group with currently unmet needs. In this collaborative study, we identified 362 patients from three European centers who initiated dialysis during the course of the disease. Median survival after the initiation of dialysis was 40\u2009months. Heart involvement, higher BMPC infiltration at diagnosis, and lambda light chain type were associated with inferior survival. At the time of dialysis initiation, cardiac biomarkers were prognostic for postdialysis outcome, but they did not perform the same as in patients not on dialysis. Higher FLCs levels at dialysis initiation were also prognostic, independently of cardiac biomarkers and other adverse factors. After starting dialysis, 151 patients received further treatment; median postdialysis survival for those that achieved CR\/VGPR was significantly improved with 63.8 vs. 42\u2009months for patients who achieved PR or less. In conclusion, patients with AL amyloidosis that require dialysis still represent a group of patients with poor outcomes, although, they can have prolonged postdialysis survival if they achieve deep hematologic response and have limited cardiac and clonal disease; such patients could also be considered for renal transplantation.<\/jats:p>","DOI":"10.1002\/ajh.70532","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:35:13Z","timestamp":1792593313000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Patients With\n                    <scp>AL<\/scp>\n                    Amyloidosis and End\u2010Stage Renal Disease After Initiation of Therapy"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2233-5896","authenticated-orcid":false,"given":"Lilli Sophie","family":"Sester","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Amyloidosis Center University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Amyloidosis Center University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-9422","authenticated-orcid":false,"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine University of Pavia  Pavia Italy"},{"name":"Amyloidosis Research and Treatment Center Fondazione IRCCS Policlinico San Matteo  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-1835","authenticated-orcid":false,"given":"Claudia","family":"Bellofiore","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine University of Pavia  Pavia Italy"},{"name":"Amyloidosis Research and Treatment Center Fondazione IRCCS Policlinico San Matteo  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmia","family":"Psimenou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charikleia","family":"Gakiopoulou","sequence":"additional","affiliation":[{"name":"First Department of Pathology National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"},{"name":"Department of Medicine Korea University  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine University of Pavia  Pavia Italy"},{"name":"Amyloidosis Research and Treatment Center Fondazione IRCCS Policlinico San Matteo  Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4853-5579","authenticated-orcid":false,"given":"Stefan O.","family":"Sch\u00f6nland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Amyloidosis Center University Hospital Heidelberg  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"6","key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in Renal AL Amyloidosis After Chemotherapy","volume":"29","author":"Pinney J. H.","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for Non\u2010Transplant Chemotherapy for Treatment of Systemic AL Amyloidosis: EHA\u2010ISA Working Group","volume":"30","author":"Wechalekar A. D.","year":"2023","journal-title":"Amyloid"},{"issue":"12","key":"e_1_2_9_4_1","first-page":"3042","article-title":"Characterization, Outcome and Identification of Prognostic Factors for Patients With Systemic Immunoglobulin Light\u2010Chain Amyloidosis Requiring Dialysis Prior to Initial Anti\u2010Clonal Therapy","volume":"110","author":"Sester L. S.","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201022 April 2004","volume":"79","author":"Gertz M. A.","year":"2005","journal-title":"American Journal of Hematology"},{"key":"e_1_2_9_6_1","first-page":"48","article-title":"Definition of Organ Involvement and Response to Treatment in AL Amyloidosis: An Updated Consensus Opinion","volume":"17","author":"Gertz M. A.","year":"2010","journal-title":"Amyloid"},{"issue":"15","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A Staging System for Renal Outcome and Early Markers of Renal Response to Chemotherapy in AL Amyloidosis","volume":"124","author":"Palladini G.","year":"2014","journal-title":"Blood"},{"issue":"17","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European Collaborative Study of Treatment Outcomes in 346 Patients With Cardiac Stage III AL Amyloidosis","volume":"121","author":"Wechalekar A. D.","year":"2013","journal-title":"Blood"},{"issue":"36","key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes","volume":"30","author":"Palladini G.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the Definition of Complete Haematologic Response in Light\u2010Chain (AL) Amyloidosis","volume":"28","author":"Palladini G.","year":"2021","journal-title":"Amyloid"},{"issue":"6","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients With Chronic Kidney Disease","volume":"3","author":"Hutchison C. A.","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"9","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining New Reference Intervals for Serum Free Light Chains in Individuals With Chronic Kidney Disease: Results of the iStopMM Study","volume":"12","author":"Long T. E.","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"8","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/ajh.27716","article-title":"Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis","volume":"100","author":"Theodorakakou F.","year":"2025","journal-title":"American Journal of Hematology"},{"issue":"20","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal Gammopathy of Renal Significance","volume":"384","author":"Leung N.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.27001","article-title":"Prospective Phase 2 Trial of Daratumumab With Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: The DARE Study","volume":"98","author":"Kastritis E.","year":"2023","journal-title":"American Journal of Hematology"},{"issue":"3","key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.15935","article-title":"Venetoclax Pharmacokinetics in Participants With End\u2010Stage Renal Disease Undergoing Haemodialysis","volume":"90","author":"Noorani B.","year":"2024","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"12","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201cReal\u2010Life\u201d Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma\u2014The Mayo Clinic Experience","volume":"11","author":"Vaxman I.","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"5","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13807","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Venetoclax, a Selective B\u2010Cell Lymphoma\u20102 Inhibitor","volume":"17","author":"Salem A. H.","year":"2024","journal-title":"Clinical and Translational Science"},{"issue":"12","key":"e_1_2_9_19_1","article-title":"Retrospective Cohort Study of Treatment With BCL\u20102 Inhibitor Venetoclax in Advanced AL Amyloidosis","volume":"11","author":"Veelken K.","year":"2026","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax Induces Deep Hematologic Remissions in t(11;14) Relapsed\/Refractory AL Amyloidosis","volume":"11","author":"Premkumar V. J.","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1309\/M7AAXA0J1THMNCDF","article-title":"Correlation and Prognostic Utility of B\u2010Type Natriuretic Peptide and Its Amino\u2010Terminal Fragment in Patients With Chronic Kidney Disease","volume":"126","author":"Austin W. J.","year":"2006","journal-title":"American Journal of Clinical Pathology"},{"issue":"3","key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and Validation of a Survival Staging System Incorporating BNP in Patients With Light Chain Amyloidosis","volume":"133","author":"Lilleness B.","year":"2019","journal-title":"Blood"},{"issue":"34","key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High\u2010Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis","volume":"31","author":"Kourelis T. V.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone Marrow Plasma Cells 20% or Greater Discriminate Presentation, Response, and Survival in AL Amyloidosis","volume":"34","author":"Muchtar E.","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients With Light\u2010Chain Amyloidosis and Low Free Light\u2010Chain Burden Have Distinct Clinical Features and Outcome","volume":"130","author":"Milani P.","year":"2017","journal-title":"Blood"},{"issue":"5","key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL Amyloidosis Patients With Low Amyloidogenic Free Light Chain Levels at First Diagnosis Have an Excellent Prognosis","volume":"130","author":"Dittrich T.","year":"2017","journal-title":"Blood"},{"issue":"8","key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of Renal Transplantation in Patients With AL Amyloidosis: An International Collaboration Through the International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi A.","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"12","key":"e_1_2_9_28_1","first-page":"3032","article-title":"Revised Renal Stratification and Progression Models for Predicting Long\u2010Term Renal Outcomes in Immunoglobulin Light Chain Amyloidosis","volume":"110","author":"Rauf M. U.","year":"2025","journal-title":"Haematologica"},{"issue":"14","key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","article-title":"Growth Differentiation Factor\u201015 Is a New Biomarker for Survival and Renal Outcomes in Light Chain Amyloidosis","volume":"131","author":"Kastritis E.","year":"2018","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70532","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:35:16Z","timestamp":1792593316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":28,"alternative-id":["10.1002\/ajh.70532"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70532","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2026-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajh.70532"}}